Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method

Selpercatinib (SLP; brand name Retevmo(®)) is a selective and potent RE arranged during transfection (RET) inhibitor. On 21 September 2022, the FDA granted regular approval to SLP (Retevmo, Eli Lilly, and Company). It is considered the only and first RET inhibitor for adults with metastatic or local...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W., AlRabiah, Haitham, Mostafa, Gamal A.E., Bakheit, Ahmed H., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054762/
https://www.ncbi.nlm.nih.gov/pubmed/36985590
http://dx.doi.org/10.3390/molecules28062618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054762/
https://www.ncbi.nlm.nih.gov/pubmed/36985590
http://dx.doi.org/10.3390/molecules28062618

Ejemplares similares